Hydroxychloroquine
Hydroxychloroquine Price range: $ 50,00 through $ 1 450,00
Back to products
Hytrin
Hytrin Price range: $ 57,00 through $ 451,00

Hypernil

Price range: $ 63,00 through $ 248,00

Hypernil is a highly effective medication primarily utilized for the management of high blood pressure and various cardiovascular conditions. This therapeutic agent works as an ACE inhibitor to help relax blood vessels, ensuring smoother blood flow throughout the body. In addition to treating hypertension, it is frequently used to manage symptoms of heart failure and improve overall cardiac function. Consistent use of this treatment can significantly reduce the risk of serious health complications like strokes and heart attacks. Hypernil provides a reliable solution for maintaining healthy blood pressure levels and supporting long-term heart health.

Active substance: lisinopril
SKU: Hypernil Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Hypernil belongs to the class of medications known as angiotensin-converting enzyme (ACE) inhibitors. It is prescribed for the management of hypertension (high blood pressure) and symptomatic heart failure in adult patients. Dispensed strictly in accordance with federal and state regulations, this prescription therapy requires regular clinical evaluation.

Effective blood pressure management with Hypernil helps reduce the risk of secondary cardiovascular complications, including stroke and myocardial infarction. Clinical monitoring ensures that dosage adjustments remain aligned with therapeutic goals and renal safety metrics.

Parameter Clinical Details
Active ingredient Enalapril maleate
Therapeutic class Angiotensin-Converting Enzyme (ACE) Inhibitor
Dosage form Oral tablet
Route of administration Oral
Primary purpose Blood pressure reduction and heart failure management
Prescription status Prescription (Rx) only

Clinical and Pharmacological Profile of Hypernil

How the drug works

Enalapril maleate is an oral prodrug that undergoes bioactivation via hepatic hydrolysis to form its active metabolite, enalaprilat. Enalaprilat competitively inhibits angiotensin-converting enzyme (ACE), a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. By suppressing angiotensin II production, Hypernil reduces systemic vascular resistance, lowers arterial blood pressure, and decreases aldosterone secretion. The reduction in aldosterone leads to a slight decrease in sodium retention while potentially elevating serum potassium concentrations. Additionally, ACE inhibition decreases the degradation of bradykinin, a vasodilatory peptide, which contributes to the overall blood pressure-lowering effect.

Main uses

Hypernil is primarily indicated for the treatment of essential and renovascular hypertension. It is utilized both as monotherapy and in combination with other antihypertensive agents, such as thiazide diuretics. Furthermore, Hypernil is indicated for the management of symptomatic heart failure, where it is co-administered with digitalis and diuretics to improve survival rates and reduce hospitalization frequencies. The medication is also prescribed for patients with asymptomatic left ventricular dysfunction (ejection fraction ≤ 35%) to delay the progression to clinical heart failure and decrease the incidence of myocardial infarction. Off-label applications, such as diabetic nephropathy management, must be explicitly evaluated and monitored by a qualified prescriber.

Dosing schedule

Dosage parameters for Hypernil are individualized based on patient clinical response, renal function, and concomitant fluid or salt depletion. For initial hypertension management in adults, the standard starting dose typically ranges from 2.5 mg to 5 mg once daily. Adjustments are titrated according to blood pressure measurements, with maintenance dosages generally falling between 10 mg and 40 mg daily, administered either as a single dose or divided into two equal doses. In patients with severe renal impairment (creatinine clearance less than 30 mL/min), initial dosing starts at lower thresholds to prevent accumulation. Administration does not depend on food intake, but consistency in daily timing is recommended.

What happens in the body

Following oral administration, enalapril is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within approximately one hour. The extent of oral absorption is approximately 60% and is unaffected by the presence of food in the stomach. Peak serum levels of the active metabolite, enalaprilat, occur between 3 and 4 hours after ingestion. Enalaprilat displays an effective half-life of approximately 11 hours during repeated dosing. Elimination occurs primarily through renal excretion, with over 90% of the administered dose recovered in the urine as intact enalapril or enalaprilat. Consequently, impaired kidney clearance significantly prolongs the elimination profile of the drug.

What not to combine

Concomitant administration of Hypernil with potassium-sparing diuretics (such as spironolactone, triamterene, or amiloride) or potassium supplements elevates the risk of severe hyperkalemia. Co-administration with nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, may attenuate the antihypertensive efficacy of Hypernil and increase the risk of acute renal dysfunction, particularly in elderly or volume-depleted patients. Concurrent use of lithium with ACE inhibitors can lead to decreased renal clearance of lithium, resulting in toxic serum lithium concentrations. Simultaneous use with aliskiren in patients with diabetes mellitus or renal impairment is contraindicated due to heightened risks of hypotension, hyperkalemic events, and renal injury.

Adverse reactions

Clinical trials and post-marketing surveillance identify dizziness, headache, and fatigue as common neurological adverse reactions associated with Hypernil therapy. A characteristic dry, non-productive cough mediated by accumulation of bradykinin occurs in a subset of patients; this reaction typically resolves only upon treatment cessation. Cardiovascular effects may include symptomatic orthostatic hypotension, particularly following the initial dose or dosage escalation. Laboratory abnormalities include elevations in serum creatinine and blood urea nitrogen (BUN), as well as hyperkalemia. Less frequent but severe adverse effects involve agranulocytosis, neutropenia, and cholestatic jaundice.

Important precautions

Hypernil carries a boxed warning regarding fetal toxicity. Administration of ACE inhibitors during the second and third trimesters of pregnancy can cause severe fetal injury, renal failure, oligohydramnios, skeletal deformities, and neonatal death; treatment must be discontinued immediately upon detection of pregnancy. Patients with a history of angioedema related to prior ACE inhibitor therapy must not receive Hypernil due to the risk of life-threatening airway obstruction. Monitoring of serum electrolytes and renal function parameters is required prior to initiating therapy and periodically throughout the treatment course. Caution is advised in patients with aortic stenosis or severe ischemic heart disease.

What to avoid while taking it

Patients taking Hypernil should avoid over-the-counter potassium supplements and salt substitutes containing potassium chloride unless explicitly directed by a physician. Alcohol consumption should be limited or avoided, as ethanol can potentiate the hypotensive effect of Hypernil, increasing the likelihood of lightheadedness, dizziness, and syncope. Strenuous exercise or exposure to hot weather without adequate fluid intake may lead to volume depletion, aggravating blood pressure drops. Patients should refrain from self-administering over-the-counter NSAID analgesics without professional consultation.

Red flags

Immediate emergency medical evaluation is mandatory if signs of angioedema occur, including swelling of the face, lips, tongue, glottis, or throat that hampers swallowing or breathing. Sudden severe dizziness, fainting, or lightheadedness upon standing signals marked hypotension requiring immediate clinical intervention. Symptoms suggestive of high serum potassium, such as severe muscle weakness, slow pulse, or cardiac arrhythmias, warrant urgent blood testing. Severe abdominal pain accompanied by nausea may indicate intestinal angioedema and requires prompt diagnosis.

What to do if you miss a dose

If a scheduled dose of Hypernil is missed, it should be taken as soon as remembered on the same day. However, if the time approaches the next scheduled dose, the missed dose should be skipped entirely, resuming the regular dosing protocol. Patients must never double the dose to make up for a missed administration, as doubling increases the potential for acute hypotensive episodes and renal strain.

Storage and expiration

Hypernil tablets should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). The medication must be kept in a tightly closed container protected from excessive moisture, heat, and direct light exposure. Avoid storing the product in high-humidity environments such as bathroom cabinets. Discard any medication that has passed its expiration date as indicated on the original prescription packaging.

Frequently asked questions

Is a persistent dry cough a common side effect of Hypernil?

Yes, a dry, non-productive cough is a well-documented class effect of ACE inhibitors like Hypernil, occurring in approximately 5% to 15% of treated individuals. This cough is thought to result from the pulmonary accumulation of bradykinin and substance P due to ACE inhibition. It does not respond to standard cough suppressants and typically resolves within a few days to weeks after discontinuing the drug under medical supervision.

What steps should be taken if excessive low blood pressure occurs?

If symptoms of excessive blood pressure reduction–such as pronounced lightheadedness or feeling faint–occur, the individual should lie down in a supine position with legs elevated. Transient hypotension is not an absolute contraindication to continued therapy, but recurring episodes necessitate consultation with the prescribing physician to adjust the dosage or evaluate fluid status.

Can Hypernil be safely combined with potassium supplements?

Combining Hypernil with potassium supplements or salt substitutes containing potassium is generally discouraged unless strictly monitored by a clinician. Because ACE inhibitors reduce aldosterone secretion, potassium excretion by the kidneys decreases. Concurrent potassium intake significantly raises the risk of hyperkalemia, which can induce severe cardiac rhythm disturbances.

How does kidney dysfunction alter the clearance of Hypernil?

Hypernil’s active metabolite, enalaprilat, is primarily eliminated via renal excretion. In patients with reduced renal clearance (creatinine clearance below 30 mL/min), elimination is prolonged, leading to higher baseline serum concentrations. Consequently, dosage intervals or total daily amounts must be reduced to avoid drug accumulation and related adverse reactions.

Should Hypernil treatment be stopped abruptly if blood pressure normalizes?

No, Hypernil therapy should not be discontinued abruptly without physician guidance, even if blood pressure measurements reach target ranges. Normalization of blood pressure indicates that the medication is effective, not that the underlying condition is cured. Sudden cessation can cause blood pressure to return to hypertensive levels, elevating long-term cardiovascular risks.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

5mg

,

10mg

Package

60 tabs

,

90 tabs

,

120 tabs

,

180 tabs

,

270 tabs

,

360 tabs

Ενεργός Ουσία